Elsevier Inc.

SHERPA: Unknown

People

  1. Lee
    Lee
  2. Giralt
    Giralt
  3. Mulhall
    Mulhall
  4. Perales
    Perales
  5. Yorke
    Yorke
  6. Wolden
    Wolden
  7. Rusch
    Rusch
  8. Yamada
    Yamada
  9. Zhang
    Zhang
  10. Travis
    Travis

Groups

  1. Department of Medicine (4218)
  2. Surgery (2710)
  3. Survivorship Research (2394)
  4. Solid Tumor Oncology Division (2240)
  5. Radiation Oncology, Department of (2047)
  6. GSK Faculty (1884)
  7. Center for Hematologic Malignancies (1669)
  8. Hematologic Malignancies, Division of (1531)
  9. Sloan Kettering Institute Faculty (1376)
  10. Medical Physics (1209)
Search Within
Formats
  1. Journal Article (6733)
  2. Meeting Abstract (4312)
  3. Review (631)
  4. Book Section (542)
  5. Editorial (253)
  6. Conference Paper (132)
  7. Correspondence (92)
  8. Guidelines (85)
  9. Research Letter (33)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4218)
  2. Surgery (2710)
  3. Survivorship Research (2394)
  4. Solid Tumor Oncology Division (2240)
  5. Radiation Oncology, Department of (2047)
  6. GSK Faculty (1884)

More Groups

People
  1. Nancy Lee (413)
  2. Michael Zelefsky (401)
  3. Sergio Giralt (386)
  4. John Mulhall (381)
  5. Miguel-Angel Perales (303)
  6. Andreas Rimner (292)

More People

Years
  1. 2026 (3)
  2. 2025 (397)
  3. 2024 (708)
  4. 2023 (680)
  5. 2022 (745)
  6. 2021 (665)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2629)
  2. Journal of Thoracic Oncology (973)
  3. Biology of Blood and Marrow Transplantation (815)
  4. European Journal of Cancer (529)
  5. Journal of Sexual Medicine (440)
  6. Clinical Lymphoma, Myeloma and Leukemia (402)

More Publications

Results (12842)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
    Meeting Abstract

    Rodon, J.; Jänne, P. A.; Leventakos, K.; George, B.; Henry, J. T.; Johnson, M. L.; Papadopoulos, K. P.; Batista, A. I.; Spira, C. P.; Zhao, Y.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (trial in progress)
    Meeting Abstract

    Baldini, C.; Patnaik, A.; Lakhani, N.; Call, J.; Galsky, M.; Garmezy, B.; Wei, A.; Carter, L.; Powles, T.; Siefker-Radtke, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Targeted CRISPR-Knockout (KO) screening to identify FOXF1 regulators and therapeutic strategies in gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Tomas, F.; Cho, W. H.; Li, D.; Callychurn, V. R.; Wang, N.; Yu, C.; Chi, P.
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins
    Meeting Abstract

    Mukherjee, R.; Vanaja, K. G.; Sharma, M.; Solomon, H.; De Stanchina, E.; Chandarlapaty, S.; Rosen, N.
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
    Meeting Abstract

    Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors
    Meeting Abstract

    Hong, D. S.; Papadopoulos, K.; Kim, D. W.; Parikh, A.; Barve, M.; Powderly, J.; Starodub, A.; Strickler, J.; Li, B. T.; Oberstein, P.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations
    Meeting Abstract

    Loriot, Y.; Zhang, A.; Hansen, A.; Mantia, C.; Boni, V.; Weickhardt, A.; Yu, E. Y.; Robert, M.; Iyer, G.; Murtha, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Identification of biomarkers of response and the mechanism of action of a selective androgen receptor modulator in estrogen receptorpositive breast cancer patient-derived xenografts
    Meeting Abstract

    Monserrat, L.; García García, J.; Gutiérrez, C. M.; Viaplana, C.; Brasó-Maristany, F.; Bellet, M.; Chandarlapaty, S.; Nonell, L.; Ponomarenko, J.; Canals, F.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • First-in-human, phase 1 study of a selective RET inhibitor, LOXO-260, in patients with RET inhibitor refractory, RET-altered cancers
    Meeting Abstract

    Subbiah, V.; Drilon, A.; Bestvina, C.; Garon, E. B.; Wirth, L.; Worden, F.; Piha-Paul, S.; Rotow, J.; Johnson, M.; Kang, H.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
    Meeting Abstract

    Højgaard, M.; Yap, T. A.; Lee, E. K.; Weiss, M. C.; Lheureux, S.; Simpkins, F.; LoRusso, P.; Carneiro, B. A.; Moy, R. H.; Aguado-Fraile, E.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save